Managed Markets
Network

Journals

MORE >>>
Policy
January 18, 2019
Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia
July 11, 2018 – Kelly Fust, MS; Anju Parthan, PhD; Xiaoyan Li, PhD; Anjali Sharma, MD; Xinke Zhang, MS; Marco Campioni, PhD; Junji Lin, PhD, MS; Xuena Wang, PhD; Richard Zur, PhD; Karynsa Cetin, MPH; Melissa Eisen, MD; and David Chandler, PhD
The Importance of Teamwork in Oncology Care Transitions
February 28, 2018 – Surabhi Dangi-Garimella, PhD

Study Summaries

Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
October 23, 2018
Study Summary: Response and Progression-Free Survival at 18 Months With Lenalidomide and Dexamethasone
October 23, 2018
Study Summary: Once-Weekly Versus Twice-Weekly Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma: ARROW Interim Analysis
October 23, 2018
Study Summary: Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma
October 23, 2018
Study Summary: Cardiovascular Safety Profile of Carfilzomib in Multiple Myeloma Clinical Trials
October 18, 2018
Study Summary: Carfilzomib + Dexamethasone Versus Bortezomib (SC or IV) + Dexamethasone in Relapsed or Refractory Multiple Myeloma (ENDEAVOR Secondary Analysis)
October 18, 2018
Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma
October 18, 2018
Study Summary: The Role of Race and Ethnicity in Disease and Outcome Disparities in Multiple Myeloma
October 18, 2018
ACCOUNTABLE CARE DELIVERY CONGRESS
CONTINUING EDUCATION
CONTRIBUTORS
MEETINGS
PARTICIPATE
COMPENDIA
In Focus Blog
Press Releases
Interactive Tools
Managed Care Podcast
Panel Discussions
Week In Review
Information for Reviewers
Information for Authors
Formulary Central
Clinical Study Summaries
Study Summaries
About Us
AJAC
AJMC
EBDM
EBO
AJMC Resources
Careers
Contact Us
Privacy Policy
Terms & Conditions
Subscribe
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!